Blog

First efficacy trial of Athersys stem cell therapy yields disappointing … – MedCity News

MedCity News
Share This Story. IV drip hospital patient Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe
Athersys Inc. stem cell therapy for bowel disease fails to show ‘meaningful Crain’s Cleveland Business
Athersys stemcell therapy for bowel disease fails in studyReuters
Athersys, Inc. (NASDAQ:ATHX) Reports Disappointment In Stem Cell Study For WallStreetPR
Wall Street JournalBenzinga
all 17 news articles

…read more    

2014-04-28 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.